Natco, Lupin get USFDA nod
Natco Pharma Ltd announced the final approval of Abbreviated New Drug Application (ANDA) for Imatinib Mesylate tablets from the US Food and Drug Admin06-03-2019
06-03-2019
Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Natco & its alliance partner Lupin receive FDA approval for lmatinib Mesylate Tablets06-03-2019
Lack of new launches in near term a worry for Natco Pharma stock
Lack of significant launch visibility has led analysts to estimate net profit numbers to be little changed next year21-02-2019
Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the quarter and nine months ended December 31, 201818-02-2019
Natco Pharma hits 52-week low on disappointing December earnings
The stock dipped 7% to Rs 620 after the company reported 27 per cent drop in consolidated net profit at Rs 159 crore for the quarter ended December 2018.13-02-2019
Natco Pharma Ltd - 524816 - 22Nd February 2019 Fixed As Record Date For Payment Of Second Interim Dividend For The Year 2018-19
22nd February 2019 fixed as Record Date for payment of second Interim Dividend for the year 2018-1912-02-2019
Natco Pharma Ltd - 524816 - Board declares Second Interim Dividend
Natco Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 12, 2019, inter alia, has declared second interim dividend of Rs.3.50 ps. (Rupees three and paise fifty only) on each equityshare of face value Rs. 2/- (Rupees two only) each for the financial year 2018-2019.The said interim dividend will be paid from February 26, 2019.12-02-2019
NATCO PHARMA LTD. - 524816 - Unaudited Financial Results For The Quarter And Nine Months Ended 31St December, 2018
Unaudited Financial Results for the quarter and nine months ended 31st December, 201812-02-2019
Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This further to our earlier letter dated 05/02/2019, the Company will host an Earnings Call with Investors / Analysts at 12.00 a.m. IST on February 13, 2019 instead of 11.00 a.m. to disseminate Financial Results of the company for the quarter and nine months ended December 31, 2018. A Copy of the same is enclosed for your ready reference.07-02-2019
Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The Company will host an Earnings Call with Investors / Analysts at 11.00 a.m. IST on February 13, 201905-02-2019